These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1401 related articles for article (PubMed ID: 28495699)

  • 41. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Nasir K; Bittencourt MS; Blaha MJ; Blankstein R; Agatson AS; Rivera JJ; Miedema MD; Sibley CT; Shaw LJ; Blumenthal RS; Budoff MJ; Krumholz HM
    J Am Coll Cardiol; 2015 Oct; 66(15):1657-68. PubMed ID: 26449135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort.
    Schonmann Y; Bleich O; Matalon A; Yeshua H
    Eur J Prev Cardiol; 2018 May; 25(8):870-880. PubMed ID: 29517367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population.
    Cho YK; Jung CH; Kang YM; Hwang JY; Kim EH; Yang DH; Kang JW; Park JY; Kim HK; Lee WJ
    J Am Heart Assoc; 2016 Aug; 5(8):. PubMed ID: 27543305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal.
    Ngo-Metzger Q; Zuvekas S; Shafer P; Tracer H; Borsky AE; Bierman AS
    J Am Board Fam Med; 2019; 32(6):807-817. PubMed ID: 31704749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction.
    Miedema MD; Garberich RF; Schnaidt LJ; Peterson E; Strauss C; Sharkey S; Knickelbine T; Newell MC; Henry TD
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28404560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective Evaluation of ASCVD Risk and Statin Therapy Need in Nondiabetic Patients Based on the 2013 ACC/AHA Cholesterol Guidelines.
    Koenigsfeld C; Sayler M; Smith HL; Meyer K; Lehman N; Logemann C; Bottenberg M; Bryant G; Obermark M
    J Pharm Pract; 2017 Jun; 30(3):300-305. PubMed ID: 27026635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.
    Diao JA; Shi I; Murthy VL; Buckley TA; Patel CJ; Pierson E; Yeh RW; Kazi DS; Wadhera RK; Manrai AK
    JAMA; 2024 Sep; 332(12):989-1000. PubMed ID: 39073797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
    Pavlović J; Greenland P; Deckers JW; Kavousi M; Hofman A; Ikram MA; Franco OH; Leening MJ
    Eur J Prev Cardiol; 2018 Mar; 25(4):420-431. PubMed ID: 29171772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2013 ACC/AHA versus 2004 NECP ATP III Guidelines in the Assignment of Statin Treatment in a Korean Population with Subclinical Coronary Atherosclerosis.
    Jung CH; Lee MJ; Kang YM; Yang DH; Kang JW; Kim EH; Park DW; Park JY; Kim HK; Lee WJ
    PLoS One; 2015; 10(9):e0137478. PubMed ID: 26372638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.
    Mortensen MB; Nordestgaard BG; Afzal S; Falk E
    Eur Heart J; 2017 Feb; 38(8):586-594. PubMed ID: 28363217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease.
    Gunasekaran P; Jeevanantham V; Sharma S; Thapa R; Gupta K
    Indian Heart J; 2017; 69(4):464-468. PubMed ID: 28822512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statin Eligibility and Prescribing Across Racial, Ethnic, and Language Groups over the 2013 ACC/AHA Guideline Change: a Retrospective Cohort Analysis from 2009 to 2018.
    Heintzman J; Kaufmann J; Rodriguez CJ; Lucas JA; Boston D; April-Sanders AK; Chung-Bridges K; Marino M
    J Gen Intern Med; 2023 Oct; 38(13):2970-2979. PubMed ID: 36977971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of statin guidelines on statin utilization and costs in an employer-based primary care clinic.
    Gurgle HE; Schauerhamer MB; Rodriguez SA; McAdam-Marx C
    Am J Manag Care; 2017 Dec; 23(12):e387-e393. PubMed ID: 29261246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disparities in Guideline-Recommended Statin Use for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Gender : A Nationally Representative Cross-Sectional Analysis of Adults in the United States.
    Frank DA; Johnson AE; Hausmann LRM; Gellad WF; Roberts ET; Vajravelu RK
    Ann Intern Med; 2023 Aug; 176(8):1057-1066. PubMed ID: 37487210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
    J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
    Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF
    Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.